{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:14:34Z","timestamp":1783635274507,"version":"3.55.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clnesp.2026.103322","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:06:43Z","timestamp":1778285203000},"page":"103322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Omega-3 fatty acids in pediatric acute lymphocytic leukemia: A scoping review"],"prefix":"10.1016","volume":"74","author":[{"given":"Veridiana B.","family":"Bittencourt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana C.","family":"Schveitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8789-1744","authenticated-orcid":false,"given":"Roberto F.","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana P.","family":"Vellozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita C.","family":"Sinigaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnesp.2026.103322_bib1","series-title":"Fevereiro laranja: diagn\u00f3stico precoce das leucemias. (Orange February: early diagnosis of leukemia). Nota T\u00e9cnica. Sociedade Brasileira de Pediatria","author":"Silva","year":"2022"},{"key":"10.1016\/j.clnesp.2026.103322_bib2","series-title":"PDQ pediatric treatment editorial board. Childhood acute lymphoblastic leukemia treatment (PDQ\u00ae): health professional version. In: PDQ cancer information summaries","year":"2021"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103322_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nut.2015.06.010","article-title":"\u03c9-3 fatty acids as an adjuvant therapy ameliorates methotrexate-induced hepatotoxicity in children and adolescents with acute lymphoblastic leukemia: a randomized placebo-controlled study","volume":"32","author":"Elbarbary","year":"2015","journal-title":"Nutrition"},{"key":"10.1016\/j.clnesp.2026.103322_bib4","series-title":"S\u00edntese de Resultados e Coment\u00e1rios. INCA - Instituto Nacional de C\u00e2ncer","year":"2019"},{"issue":"7","key":"10.1016\/j.clnesp.2026.103322_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29496","article-title":"Omega 3 fatty acids can reduce early doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukemia","volume":"69","author":"El Amrousy","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103322_bib6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/01635581.2017.1247884","article-title":"Fish-oil-derived DHA-mediated enhancement of apoptosis in acute lymphoblastic leukemia cells is associated with accumulation of p53, downregulation of survivin, and Caspase-3 activation","volume":"69","author":"Sam","year":"2017","journal-title":"Nutr Cancer"},{"issue":"6","key":"10.1016\/j.clnesp.2026.103322_bib7","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.3390\/nu12061647","article-title":"A scoping review of interactions between Omega-3 long-chain polyunsaturated fatty acids and genetic variation in relation to cancer risk","volume":"12","author":"Yurko-Mauro","year":"2020","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103322_bib8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clnu.2014.11.005","article-title":"Omega-3 supplements for patients in chemotherapy and\/or radiotherapy: a systematic review","volume":"34","author":"de Aguiar Pastore Silva","year":"2015","journal-title":"Clin Nutr"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103322_bib9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.36660\/abc.20201340","article-title":"Position statement on fat consumption and cardiovascular health - 2021","volume":"116","author":"Izar","year":"2021","journal-title":"Arq Bras Cardiol"},{"issue":"4","key":"10.1016\/j.clnesp.2026.103322_bib10","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.4081\/hr.2015.6043","article-title":"Docosahexaenoic acid induces apoptosis in primary chronic lymphocytic leukemia cells","volume":"7","author":"Gui\u00e8ze","year":"2015","journal-title":"Hematol Rep"},{"issue":"2","key":"10.1016\/j.clnesp.2026.103322_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/01635589309514245","article-title":"Omega-3 fatty acid modification of membrane structure and function. II. Alteration by docosahexaenoic acid of tumor cell sensitivity to immune cytolysis","volume":"19","author":"Pascale","year":"1993","journal-title":"Nutr Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.clnesp.2026.103322_bib12","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.1017\/S0007114512001651","article-title":"Interactions between dietary n-3 fatty acids and genetic variants and risk of disease","volume":"107","author":"Corella","year":"2012","journal-title":"Br J Nutr"},{"issue":"2","key":"10.1016\/j.clnesp.2026.103322_bib13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.12968\/bjon.2012.21.2.76","article-title":"Acute leukaemia: making sense of a complex blood cancer","volume":"21","author":"Meenaghan","year":"2012","journal-title":"Br J Nurs"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103322_bib14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jped.2018.07.013","article-title":"Treatment outcomes of children with acute lymphoblastic leukemia in a middle-income developing country: high mortalities, early relapses, and poor survival","volume":"96","author":"Abdelmabood","year":"2020","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.clnesp.2026.103322_bib15","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/oxfordjournals.bmb.a011577","article-title":"Geographic and ethnic variations in the incidence of childhood cancer","volume":"52","author":"Stiller","year":"1996","journal-title":"Br Med Bull"},{"issue":"2","key":"10.1016\/j.clnesp.2026.103322_bib16","first-page":"83","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.clnesp.2026.103322_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1590\/S1519-38292007000400009","article-title":"Fatores progn\u00f3sticos em crian\u00e7as e adolescentes com Leucemia Linf\u00f3ide Aguda","volume":"7","author":"Leite","year":"2007","journal-title":"Rev Bras Saude Mater Infant"},{"key":"10.1016\/j.clnesp.2026.103322_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.mam.2018.04.001","article-title":"Omega-3 fatty acids, membrane remodeling and cancer prevention","volume":"64","author":"Fuentes","year":"2018","journal-title":"Mol Aspects Med"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103322_bib19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/nu2030355","article-title":"Omega-3 fatty acids and inflammatory processes","volume":"2","author":"Calder","year":"2010","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103322_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pcl.2014.09.004","article-title":"Biology of childhood acute lymphoblastic leukemia","volume":"62","author":"Bhojwani","year":"2015","journal-title":"Pediatr Clin North Am"},{"issue":"9881","key":"10.1016\/j.clnesp.2026.103322_bib21","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clnesp.2026.103322_bib22","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3390\/antiox10101627","article-title":"Omega\u22123 polyunsaturated fatty acids (PUFAs): emerging plant and microbial sources, oxidative stability, bioavailability, and health benefits\u2014A review","volume":"10","author":"Saini","year":"2021","journal-title":"Antioxidants"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103322_bib23","first-page":"592S","article-title":"Mechanisms of action of (n-3) fatty acids","volume":"142","author":"Calder","year":"2012","journal-title":"J Nutr 1o de mar\u00e7o de"},{"key":"10.1016\/j.clnesp.2026.103322_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/143109","article-title":"Omega-3 polyunsaturated fatty acids: the way forward in times of mixed evidence","author":"Weylandt","year":"2015","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103322_bib25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10555-015-9572-2","article-title":"Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials","volume":"34","author":"Nabavi","year":"2015","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"10.1016\/j.clnesp.2026.103322_bib26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.canlet.2008.03.044","article-title":"Multi-targeted therapy of cancer by omega-3 fatty acids","volume":"269","author":"Berquin","year":"2008","journal-title":"Cancer Lett"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103322_bib27","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2125.2012.04374.x","article-title":"Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?","volume":"75","author":"Calder","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"15","key":"10.1016\/j.clnesp.2026.103322_bib28","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.3390\/nu15153317","article-title":"Potential clinical applications of pro-resolving lipids mediators from docosahexaenoic acid","volume":"15","author":"Beyer","year":"2023","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.clnesp.2026.103322_bib29","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1080\/01635581.2020.1781201","article-title":"Safety of eicosapentaenoic acid in cancer treatment: effect on cancer cells and chemotherapy in vitro","volume":"73","author":"Akta\u015f","year":"2021","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.clnesp.2026.103322_bib30","series-title":"Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids [Internet]","year":"2005"},{"issue":"5","key":"10.1016\/j.clnesp.2026.103322_bib31","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1042\/BST20160474","article-title":"Omega-3 fatty acids and inflammatory processes: from molecules to man","volume":"45","author":"Calder","year":"2017","journal-title":"Biochem Soc Trans"},{"issue":"6","key":"10.1016\/j.clnesp.2026.103322_bib32","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.3390\/nu13061800","article-title":"Omega-3 fatty acids and their role in pediatric cancer","volume":"13","author":"Podpeskar","year":"2021","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103322_bib33","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.pharmthera.2013.10.010","article-title":"Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease","volume":"141","author":"Yates","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103322_bib34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/nu2030355","article-title":"Omega-3 fatty acids and inflammatory processes","volume":"2","author":"Calder","year":"2010","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103322_bib35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","article-title":"Reprogramming of fatty acid metabolism in cancer","volume":"122","author":"Koundouros","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clnesp.2026.103322_bib36","series-title":"Joint WHO\/FAO expert consultation on diet, nutrition and the prevention of chronic diseases (2002: geneva, Switzerland) diet, nutrition and the prevention of chronic diseases: report of a joint WHO\/FAO expert consultation","first-page":"149","year":"2003"},{"key":"10.1016\/j.clnesp.2026.103322_bib37","first-page":"1","article-title":"Report of an expert consultation","volume":"91","year":"2010","journal-title":"FAO Food Nutr Pap"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103322_bib38","first-page":"1461","article-title":"Scientific opinion on dietary reference values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol","volume":"8","year":"2010","journal-title":"EFSA J"},{"issue":"7","key":"10.1016\/j.clnesp.2026.103322_bib39","first-page":"2815","article-title":"Scientific opinion related to the tolerable upper intake level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA)","volume":"10","year":"2012","journal-title":"EFSA J"},{"issue":"4","key":"10.1016\/j.clnesp.2026.103322_bib40","doi-asserted-by":"crossref","first-page":"950","DOI":"10.11124\/JBIES-21-00483","article-title":"What are scoping reviews? Providing a formal definition of scoping reviews as a type of evidence synthesis","volume":"20","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103322_bib41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Methodol"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103322_bib42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/XEB.0000000000000050","article-title":"Guidance for conducting systematic scoping reviews","volume":"13","author":"Peters","year":"2015","journal-title":"Int J Evid Base Healthc"},{"issue":"7","key":"10.1016\/j.clnesp.2026.103322_bib43","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.clnesp.2026.103322_bib44","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0887-2333(02)00095-4","article-title":"Ranking the toxicity of fatty acids on jurkat and raji cells by flow cytometric analysis","volume":"16","author":"Lima","year":"2002","journal-title":"Toxicol Vitro"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103322_bib45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0167-4889(00)00128-2","article-title":"Docosahexaenoic acid induces apoptosis in Jurkat cells by a protein phosphatase-mediated process","volume":"1499","author":"Siddiqui","year":"2001","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.1016\/j.clnesp.2026.103322_bib46","first-page":"1673","article-title":"Docosahexaenoic acid sensitizes leukemia lymphocytes to barasertib and everolimus by ROS-dependent mechanism without affecting the level of ROS and viability of normal lymphocytes","volume":"36","author":"Zhelev","year":"2016","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103322_bib47","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.21873\/anticanres.16268","article-title":"Docosahexaenoic acid potentiates the anticancer effect of the Menadione\/Ascorbate redox couple by increasing mitochondrial superoxide and accelerating ATP depletion","volume":"43","author":"Ivanova","year":"2023","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.clnesp.2026.103322_bib48","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.jacl.2018.05.021","article-title":"Combination therapy of omega-3 fatty acids and acipimox for children with hypertriglyceridemia and acute lymphoblastic leukemia","volume":"12","author":"Salvador","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"9","key":"10.1016\/j.clnesp.2026.103322_bib49","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1080\/01635581.2020.1803934","article-title":"Effect of fish oil supplementation on hyperlipidemia during Childhood Acute lymphoblastic leukemia treatment \u2013 a pilot Study","volume":"73","author":"Laumann","year":"2021","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.clnesp.2026.103322_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1120364","article-title":"Effect of long-chain omega-3 polyunsaturated fatty acids on cardiometabolic factors in children with acute lymphoblastic leukemia undergoing treatment: a secondary analysis of a randomized controlled trial","volume":"14","author":"Barbosa-Cortes","year":"2023","journal-title":"Front Endocrinol"},{"issue":"9","key":"10.1016\/j.clnesp.2026.103322_bib51","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.clnu.2023.06.022","article-title":"Pilot study on the effect of supplementation with long-chain \u03c9-3 polyunsaturated fatty acids on body composition in children with acute lymphoblastic leukemia: randomized clinical trial","volume":"42","author":"Barbosa-Cort\u00e9s","year":"2023","journal-title":"Clin Nutr"},{"issue":"15","key":"10.1016\/j.clnesp.2026.103322_bib52","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.3390\/nu17152526","article-title":"Impact of Omega-3 and vitamin D supplementation on bone turnover markers in children with leukemia: Follow-Up during and after supplementation","volume":"17","author":"Barbosa-Cort\u00e9s","year":"2025","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.clnesp.2026.103322_bib53","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3390\/cancers13061206","article-title":"N-3 long-chain polyunsaturated fatty acids, eicosapentaenoic and docosahexaenoic acid, and the role of supplementation during cancer treatment: a scoping review of Current clinical evidence","volume":"13","author":"Newell","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.clnesp.2026.103322_bib54","first-page":"75","article-title":"The impact of n-3 polyunsaturated fatty acids in patients with cancer: emerging themes","volume":"28","author":"van der Meij","year":"2025","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103322_bib55","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/01635581.2024.2435079","article-title":"The use of dietary supplements for the management of adverse effects of treatment in children and adolescents with leukemia: a scoping review","volume":"77","author":"Steffens","year":"2025","journal-title":"Nutr Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.clnesp.2026.103322_bib56","article-title":"\u00c1cidos grasos poliinsaturados omega-3 en pacientes pedi\u00e1tricos con leucemia linfobl\u00e1stica aguda [Omega-3 polyunsaturated fatty acids in pediatric patients with acute lymphoblastic leukemia]","volume":"63","author":"Morales-Montes","year":"2025","journal-title":"Rev Med Inst Mex Seguro Soc"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457726004183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457726004183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:24:39Z","timestamp":1783632279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405457726004183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":56,"alternative-id":["S2405457726004183"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2026.103322","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omega-3 fatty acids in pediatric acute lymphocytic leukemia: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2026.103322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103322"}}